School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Leukemia. 2023 Jul;37(7):1454-1463. doi: 10.1038/s41375-023-01918-9. Epub 2023 May 11.
Chronic lymphocytic leukaemia (CLL) cells can express unmutated (U-CLL) or mutated (M-CLL) immunoglobulin heavy chain (IGHV) genes with differing clinical behaviours, variable B cell receptor (BCR) signalling capacity and distinct transcriptional profiles. As it remains unclear how these differences reflect the tumour cells' innate pre/post germinal centre origin or their BCR signalling competence, we applied mRNA/miRNA sequencing to 38 CLL cases categorised into three subsets by IGHV mutational status and BCR signalling capacity. We identified 492 mRNAs and 38 miRNAs differentially expressed between U-CLL and M-CLL, but only 9 mRNAs and 0 miRNAs associated with BCR competence within M-CLL. Of the IGHV-associated miRNAs, (14/38 (37%)) derived from chr14q32 clusters where all miRNAs were co-expressed with the MEG3 lncRNA from a cancer associated imprinted locus. Integrative analysis of miRNA/mRNA data revealed pronounced regulatory potential for the 14q32 miRNAs, potentially accounting for up to 25% of the IGHV-related transcriptome signature. GAB1, a positive regulator of BCR signalling, was potentially regulated by five 14q32 miRNAs and we confirmed that two of these (miR-409-3p and miR-411-3p) significantly repressed activity of the GAB1 3'UTR. Our analysis demonstrates a potential key role of the 14q32 miRNA locus in the regulation of CLL-related gene regulation.
慢性淋巴细胞白血病 (CLL) 细胞可以表达未突变 (U-CLL) 或突变 (M-CLL) 的免疫球蛋白重链 (IGHV) 基因,具有不同的临床行为、可变的 B 细胞受体 (BCR) 信号转导能力和不同的转录谱。由于尚不清楚这些差异如何反映肿瘤细胞的先天生发中心起源或其 BCR 信号转导能力,我们应用 mRNA/miRNA 测序对 38 例 CLL 病例进行分类,这些病例根据 IGHV 突变状态和 BCR 信号转导能力分为三个亚组。我们在 U-CLL 和 M-CLL 之间鉴定了 492 个差异表达的 mRNAs 和 38 个 miRNAs,但在 M-CLL 中只有 9 个 mRNAs 和 0 个 miRNAs 与 BCR 能力相关。在与 IGHV 相关的 miRNAs 中,(14/38(37%))来自 chr14q32 簇,所有 miRNA 与来自癌症相关印记基因座的 MEG3 lncRNA 共表达。miRNA/mRNA 数据的综合分析显示,14q32 miRNAs 具有显著的调节潜力,可能占 IGHV 相关转录组特征的高达 25%。GAB1 是 BCR 信号的正调节剂,可能受到 14q32 miRNAs 的调节,我们证实其中两个 (miR-409-3p 和 miR-411-3p) 显著抑制了 GAB1 3'UTR 的活性。我们的分析表明,14q32 miRNA 基因座在调节 CLL 相关基因调节中可能具有关键作用。